CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting

10 2 2025 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference

04 2 2025 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

28 1 2025 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

22 1 2025 06:05:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

20 12 2024 08:46:04 提供 NetDania Notify

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

19 12 2024 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

25 11 2024 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

12 11 2024 15:05:01 提供 Nasdaq GlobeNewswire

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

07 11 2024 08:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

06 11 2024 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

04 11 2024 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

31 10 2024 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

22 10 2024 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

09 10 2024 05:30:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

27 8 2024 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

12 8 2024 15:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

08 8 2024 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

01 8 2024 06:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China

29 7 2024 15:05:00 提供 Nasdaq GlobeNewswire

Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET

22 7 2024 11:00:00 提供 Nasdaq GlobeNewswire